Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial

Woo, Se JoonSadda, SriniVas R.Bradvica, MarioVajas, AttilaSagong, MinErnest, JanStudnicka, JanVeith, MiroslavWylegala, EdwardPatel, SunilYun, CheolminOrski, MichalAstakhov, SergeiTóth-Molnár, EditCsutak, AdrienneEnyedi, LajosChoi, WooreeOh, InkyungJang, Hyerin2024-01-102024-01-102023BMJ Open Ophthalmology. -8 : 1 (2023), p. 1-10. -(cikkazonosító)e001561. -BMJ Open Ophth. - 2397-32692397-3269https://hdl.handle.net/2437/364855Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trialfolyóiratcikkopen access journalhttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM117778OrvostudományokKlinikai orvostudományokhttps://bmjophth.bmj.com/lookup/doi/10.1136/bmjophth-2023-001561szerzőhttp://dx.doi.org/10.1136/bmjophth-2023-0015612024-01-1000113478330000385180756313